PATENT CLAIM ANALYSIS

Application Number: 15925556
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "134100"]

Abstract:
In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.

Claim (Index 30):
The method of  claim 28 , wherein the antibody is chimeric.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 90.0
- Lexical Diversity: 1.44444
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14814040', '13403657', '15664172', '12796307', '13657649']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7442115264636863
- 35 USC 102 Novelty (BERT): 0.5427739802773716
- Combined Prediction Score: 0.7240677718450548
- Mean Citation Score: 375.31871200000006
- Max Citation Score: 379.10403
- Similarity Product: 277.5820596820772

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test